Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

License negotiation between Ambrilia Biopharma Inc. and Merck & Co.

Fasken
Reading Time 1 minute read Subscribe
Member of the license negotiation team (clinical phase 1) between Ambrilia Biopharma Inc. and Merck & Co. (reported value: $232,000,000)

    Subscribe

    Receive email updates from our team

    Subscribe